Soligenix Inc (NQ: SNGX )

3.650 -0.210 (-5.44%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Soligenix Inc

< Previous 1 2 3 4 5 6 7 8 Next >

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

July 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Soligenix's HyBryte Treatment Now Within Reach for Rare Cancer Patients

July 26, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Exposures Product Safety

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact

July 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Soligenix Partners With SERB Pharmaceuticals To Supply Ricin Antigen For Ricin Toxin Poisoning Treatment

July 25, 2022

Via Benzinga

Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study

July 20, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday

May 11, 2022

On Wednesday, 807 companies reached new 52-week lows.

Via Benzinga

Recap: Soligenix Q4 Earnings

March 29, 2022

Soligenix (NASDAQ:SNGX) reported its Q4 earnings results on Tuesday, March 29, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

July 20, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session

July 07, 2022

Gainers

Via Benzinga

Soligenix Gets FDA Nod For Mid-Stage Psoriasis Study

June 28, 2022

The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s (NASDAQ: SNGX) Investigational New Drug (IND) application for Phase 2a clinical trial Evaluating SGX302 in the treatment of patients...

Via Benzinga

The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives

June 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants

March 17, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

June 28, 2022

Via Benzinga

Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis

June 07, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

May 31, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

May 25, 2022

Via Benzinga

Soligenix, Inc. (NASDAQ: SNGX) Developing Treatments for Multiple Cancers, Vaccine Candidates (Ebola, Sudan, & Marburg)

May 17, 2022

Via Get News

Exposures COVID-19

Developing Treatments for Multiple Cancers; Vaccine Candidates (Ebola, Sudan, and Marburg) Plus a Novel Heat Stable COVID-19 & Ricin Toxin Vaccines: Soligenix, Inc. (NASDAQ: SNGX)

May 17, 2022

Via Viz Release

Exposures COVID-19

Stocks That Hit 52-Week Lows On Friday

May 13, 2022

On Friday, 153 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session

May 11, 2022

Gainers

Via Benzinga

Stocks That Hit 52-Week Lows On Friday

April 29, 2022

On Friday, 213 companies hit new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session

March 17, 2022

Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 31.0% to $1.31 during Thursday's pre-market session. The company's market cap stands at $36.7 million....

Via Benzinga

Soligenix, Inc. (NASDAQ: SNGX) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event

March 08, 2022

Via Investor Brand Network

Soligenix, Inc. (NASDAQ: SNGX) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event

March 08, 2022

Via CryptoCurrencyWire

4 Penny Stocks Insiders Are Buying

December 15, 2021

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste...

Via Benzinga

Stocks Hitting New 52-Week Lows Today

January 03, 2022

On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...

Via Benzinga

Soligenix Proof of Concept Uncovers Potential Treatment Option for the World's 125 Million Psoriasis Sufferers

November 30, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Exposures Product Safety

56 Biggest Movers From Yesterday

November 24, 2021

Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating...

Via Benzinga

36 Stocks Moving In Tuesday's Mid-Day Session

November 23, 2021

Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares jumped 216.6% to $7.00 after the company announced its subsidiary Pasithea Clinics has been approved to provide...

Via Benzinga

21 Stocks Moving In Tuesday's Pre-Market Session

November 23, 2021

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 201% to $4.00 in pre-market trading. The company filed proxy statement for annual meeting after the market close on...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.